



Market Announcement

3 May 2022

Osprey Medical Inc. (ASX: OSP) – Suspension from Quotation

Description

The securities of Osprey Medical Inc. ('OSP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSP, pending the release of an announcement regarding its strategic and funding options.

Issued by

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)

3 May 2022

Ms Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
MELBOURNE VIC 3000

By email: melissa.kostopoulos@asx.com.au & tradinghaltmelbourne@asx.com.au

Dear Ms Kostopoulos

Osprey Medical Inc. (ASX:OSP) (Osprey) – Request for Voluntary Suspension

I refer to the trading halt request of 29 April 2022 in respect of Osprey's CHESS Depository Interests (**CDIs**) quoted on the Australian Securities Exchange.

Osprey now requests, pursuant to ASX Listing Rule 17.2, that its CDIs be suspended from quotation from the commencement of trading on Tuesday, 3 May 2022 (immediately after the cessation of the trading halt).

The suspension is requested in order to provide Osprey with additional time to complete its consideration of strategic and funding options (as referred to in the trading halt request) including a possible sale of assets.

Osprey expects that:

- the suspension will continue for a period of up to 5 trading days; and
- the suspension will end upon the release of an announcement by Osprey in connection with its review of options.

Osprey confirms that it is not aware of any reason why the voluntary suspension should not be granted or any other information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely



Brendan Case
Australian Secretary